Table 1 Monoclonal antibodies approved for clinical use in oncology
Antibody name | Target | Antibody format | Application |
|---|---|---|---|
Cetuximab | EGFR | Chimeric | Colorectal, breast and lung cancer |
Panitumumab | EGFR | Human | Colorectal cancer |
Nimotuzumab | EGFR | Humanized | Head and neck cancer |
Rituximab | CD20 | Chimeric | Non-Hodgkin lymphoma |
Trastuzumab | HER2 | Humanized | Breast cancer |
Alemtuzumab | CD52 | Humanized | Chronic lymphocytic leukemia |
Bevacizumab | VEGFA | Humanized | Colorectal and lung cancer |
Ofatumumab | CD20 | Human | Chronic lymphocytic leukemia |
Ipilimumab | CTLA-4 | Human | Metastatic melanoma |
Pertuzumab | HER2 | Humanized | Breast cancer |
Denosumab | RANK Ligand | Human | Solid tumor bony metastases |
Brentuximab vedotin | CD30 | Chimeric | Hodgkin's or systemic anaplastic large cell lymphoma |
Gemtuzumabozogamicin | CD33 | Humanized | Acute myelogenous leukemia |
90Y-Ibritumomab tiuxetan | CD20 | Mouse | Low grade or transformed B cell non-Hodgkin's lymphoma |
Tositumomaband 131I-tositumomab | CD20 | Mouse | Lymphoma |